Contract DevelopmentsDHA deployment is progressing smoothly, and AMWL is confident about getting the 3-year extension for the contract, with potential revenue worth $80M.
Cost ManagementAMWL is actively taking costs out of the business, expecting R&D expense to be down 10%+ y/y, sales and marketing expense down ~25% y/y, and G&A expense down 20%+ y/y.
Financial PerformanceAmwell posted a beat on the top and bottom line in Q4, with revenue above the Street estimate and an EBITDA loss better than expected.